Patent intelligence · US
US 7306914
Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy
Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease…
Patent details — US 7306914
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 11, 2007
- Expiration
- Dec 6, 2027
- Applicant
- Odyssey Thera Inc.
- Claims
- 6
- CPC classes
- A61P, A61P43/00
Quick answer
US 7306914 (Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy) is held by Odyssey Thera Inc.. Status: granted. Granted Dec 11, 2007. Expires Dec 6, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Odyssey Thera Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61P, A61P43/00
Frequently asked questions
What is US patent 7306914?
US 7306914 (Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy) is held by Odyssey Thera Inc.. Status: granted. Granted Dec 11, 2007. Expires Dec 6, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7306914?
Odyssey Thera Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 7306914 expire?
Our index shows an expiration date of Dec 6, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.